S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver

Atai Life Sciences Stock Price, News & Analysis (NASDAQ:ATAI)

$1.12
+0.08 (+7.69%)
(As of 12/1/2023 ET)
Compare
Today's Range
$1.03
$1.15
50-Day Range
$1.04
$1.52
52-Week Range
$1.03
$3.65
Volume
1.07 million shs
Average Volume
747,515 shs
Market Capitalization
$185.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.80

Atai Life Sciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,042.9% Upside
$12.80 Price Target
Short Interest
Healthy
4.46% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.22mentions of Atai Life Sciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$81,200 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.50 out of 5 stars

Medical Sector

128th out of 951 stocks

Pharmaceutical Preparations Industry

42nd out of 436 stocks


ATAI stock logo

About Atai Life Sciences Stock (NASDAQ:ATAI)

ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; GRX-917, a deuterated etifoxine for anxiety disorders; VLS-01 a N,N-Dimethyltryptamine for treatment resistant depression (TRD); DMX-1002, an oral formulation of ibogaine, a cholinergic, glutamatergic and monoaminergic receptor modulator that is a naturally occurring psychedelic product isolated from a West African shrub for the treatment of opioid use disorders (OUD); and EMP-01, an oral formulation of an MDMA derivative being developed for the treatment of post-traumatic stress disorder. The company's other clinical programs comprise PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; and KUR-101, a formulation of deuterated mitragynine for the treatment of OUD. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

ATAI Stock Price History

ATAI Stock News Headlines

Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
ATAI Life Sciences GAAP EPS of $0.25
ATAI Life Sciences NV ATAI
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Atai Life Sciences N.V. (ATAI)
ATAI Life Sciences (ATAI) Receives a Buy from Berenberg Bank
See More Headlines
Receive ATAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atai Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/10/2023
Today
12/02/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/22/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ATAI
Fax
N/A
Employees
133
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.80
High Stock Price Target
$20.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+1,042.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-152,380,000.00
Net Margins
-20,043.11%
Pretax Margin
-18,050.30%

Debt

Sales & Book Value

Annual Sales
$334,000.00
Book Value
$1.62 per share

Miscellaneous

Free Float
116,207,000
Market Cap
$185.93 million
Optionable
Not Optionable
Beta
0.69
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Christian AngermayerMr. Christian Angermayer (Age 45)
    Founder & Chairman of the Supervisory Board
    Comp: $70k
  • Mr. Florian Brand (Age 36)
    Co-founder & CEO
    Comp: $835.44k
  • Dr. Srinivas G. Rao M.D. (Age 54)
    Ph.D., Co-Founder & Chief Scientific Officer
    Comp: $834.15k
  • Mr. Stephen B. Bardin (Age 33)
    MD & CFO (Leave of Absence)
    Comp: $651.32k
  • Ms. Anne Johnson
    Chief Accounting Officer & Interim CFO
  • Dr. Michael Raven Ph.D.
    Senior Vice President of Operations
  • Mr. Frank Stegert (Age 42)
    Vice President of Investment & Venture Management
  • Mr. Ryan Barrett
    Senior VP, General Counsel & Corporate Secretary
  • Dr. Glenn Short Ph.D.
    Senior Vice President of Early Development
  • Dr. Sahil V. Kirpekar M.D. (Age 38)
    Chief Business Officer














ATAI Stock Analysis - Frequently Asked Questions

Should I buy or sell Atai Life Sciences stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Atai Life Sciences in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATAI shares.
View ATAI analyst ratings
or view top-rated stocks.

What is Atai Life Sciences' stock price target for 2024?

4 equities research analysts have issued 1 year price targets for Atai Life Sciences' shares. Their ATAI share price targets range from $9.00 to $20.00. On average, they anticipate the company's stock price to reach $12.80 in the next year. This suggests a possible upside of 1,042.9% from the stock's current price.
View analysts price targets for ATAI
or view top-rated stocks among Wall Street analysts.

How have ATAI shares performed in 2023?

Atai Life Sciences' stock was trading at $2.66 on January 1st, 2023. Since then, ATAI shares have decreased by 57.9% and is now trading at $1.12.
View the best growth stocks for 2023 here
.

Are investors shorting Atai Life Sciences?

Atai Life Sciences saw a decrease in short interest in November. As of November 15th, there was short interest totaling 5,090,000 shares, a decrease of 9.6% from the October 31st total of 5,630,000 shares. Based on an average daily trading volume, of 526,800 shares, the short-interest ratio is presently 9.7 days. Currently, 4.5% of the shares of the company are short sold.
View Atai Life Sciences' Short Interest
.

When is Atai Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 22nd 2024.
View our ATAI earnings forecast
.

How were Atai Life Sciences' earnings last quarter?

Atai Life Sciences (NASDAQ:ATAI) issued its quarterly earnings results on Thursday, August, 10th. The company reported ($0.21) earnings per share for the quarter, hitting the consensus estimate of ($0.21). The business had revenue of $0.17 million for the quarter. Atai Life Sciences had a negative trailing twelve-month return on equity of 54.90% and a negative net margin of 20,043.11%.

What ETFs hold Atai Life Sciences' stock?
What other stocks do shareholders of Atai Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Atai Life Sciences investors own include Alphabet (GOOG), Baidu (BIDU), Costco Wholesale (COST), MannKind (MNKD), NVIDIA (NVDA), Schlumberger (SLB), Twitter (TWTR), Adobe (ADBE), Allergan (AGN) and Achaogen (AKAO).

When did Atai Life Sciences IPO?

(ATAI) raised $200 million in an initial public offering (IPO) on Friday, June 18th 2021. The company issued 14,300,000 shares at a price of $13.00-$15.00 per share. Credit Suisse, Citigroup, Cowen and Berenberg acted as the underwriters for the IPO and Cantor, RBC Capital Markets and Canaccord Genuity were co-managers.

Who are Atai Life Sciences' major shareholders?

Atai Life Sciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Mirae Asset Global Investments Co. Ltd. (0.38%), AdvisorShares Investments LLC (0.11%), Legal & General Group Plc (0.04%), American Century Companies Inc. (0.03%), HighTower Advisors LLC (0.03%) and Qube Research & Technologies Ltd (0.02%). Insiders that own company stock include Apeiron Investment Group Ltd, Christian Angermayer, Florian Brand, Gregory L Weaver and Srinivas Rao.
View institutional ownership trends
.

How do I buy shares of Atai Life Sciences?

Shares of ATAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ATAI) was last updated on 12/2/2023 by MarketBeat.com Staff

My Account -